Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00730964 · ClinicalTrials.gov registry record · Phase 4
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.
A Phase 4 study, sponsored by GE Healthcare.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,039
- Enrollment target
NCT00730964 is a Phase 4 study that has completed, run by GE Healthcare. The registered enrollment target is 1,039 participants.
The verdict
NCT00730964, a Phase 4 study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,039 participants
- Enrollment target
Study Summary
This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.
Interventions
- DRUG Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,039 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00730964
The ClinicalTrials.gov registry entry for NCT00730964 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,039 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GE Healthcare, which has 99 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP) is the first listed.
NCT00730964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00730964 about?
NCT00730964 is a clinical study titled "A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.". This prospective surveillance trial will gather safety information for Optison when it is used in routine practice.
What is the current status of trial NCT00730964?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,039 participants. The study started on 2008-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00730964?
The interventions under investigation include: Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP) (DRUG).
Who is sponsoring clinical trial NCT00730964?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.